A Multi-center, Randomized, Double-blind, Parallel Controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Anti RANKL Monoclonal Antibody Injection (MW032) and Denosumab (Xgeva®) in Subjects With Bone Metastases From Solid Tumors
Overview
- Phase
- Phase 3
- Intervention
- MW032
- Conditions
- Bone Metastases
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrollment
- 708
- Locations
- 1
- Primary Endpoint
- uNTx/uCr
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
A multi-center, randomized, double-blind, parallel controlled Phase III clinical study to evaluate the clinical efficacy and safety of MW032 and Xgeva® in patients with bone metastases from solid tumors.
Detailed Description
This is A multi-center, randomized, double-blind, parallel controlled Phase III clinical trial. The primary objective is to evaluate the clinical efficacy of MW032 and Xgeva® in patients with bone metastases from solid tumors. The secondary objective are to evaluate the clinical safety and immunogenicity of MW032 and Xgeva® in patients with bone metastases from solid tumors.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pathological confirmed malignant tumors (except hematological tumors);
- •Bone metastasis diagnosed by imaging (bone X-ray, CT scanning or magnetic resonance scanning) or pathology (bone biopsy) can be examined within 3 months before signing the informed consent,according to 《The expert consensus on clinical diagnosis and treatment of bone metastases and bone related diseases of malignant tumors (2014)》；
- •No limited of gender,age ≥ 18 years old;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2;
- •Estimated survival time was more than 6 months;
- •Subjects must have adequate organ function at baseline as defined below:① hematology: neutrophils ≥ 1,500/mcL, platelets ≥ 75,000/mcL, hemoglobin ≥ 80 g / L; ② renal function: creatinine (CR) clearance rate ≥ 30 ml / min; ③ Liver function: serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were less than or equal to 2.0 × upper normal limit (ULN) in subjects without liver metastasis; ALT and AST were less than or equal to 5.0 × ULN in subjects with liver metastasis; serum total bilirubin was less than or equal to 1.5 × ULN; ④ serum calcium (albumin correction) was more than or equal to 2.0 mmol / L (8.0 mg / dl) but less than or equal to 2.9 mmol / L (11.5 mg / dl). Note: calcium supplements should not be used at least 8 hours before serum calcium determination in screening period;
- •Subjects has understood the nature and purpose of the study, as well as the research procedure, and the subject has signed the written informed consent;
Exclusion Criteria
- •Subjects with diseases not suitable for the study,in the Investigator's opinion (according to the subject's report or medical record review), such as:Other malignant tumors (different from the malignant solid tumors required in this study protocol) occurred within 3 years before enrollment, and in the active period;Other diseases affecting bone metabolism, such as vitamin D deficiency rickets, osteomalacia and primary osteoporosis, hyperparathyroidism, osteitis deformans, etc. (excluding osteoporosis);Human immunodeficiency virus or Treponema pallidum infection;Unstable liver disease, active period of hepatitis B virus or hepatitis C virus infection;Other serious or unstable physical or mental disorders.
- •Brain metastasis.
- •Oral and dental diseases: previous or current evidence of osteomyelitis or necrosis of the jaw; acute dental or mandibular diseases, need to be treated oral surgery; planned invasive dental surgery; failed dental or oral surgery.
- •Subjects with bone metastases need radiotherapy or surgery.
- •Previous treatment with denosumab.
- •Patients who had received any kind of intravenous or oral bisphosphonates before administration of the first study drug.
Arms & Interventions
MW032
MW032 injection(120mg) was administered subcutaneously once every 4 weeks for a maximum of 13 consecutive doses throughout the trial, according to the investigator's assessment.
Intervention: MW032
Xgeva®
Xgeva® injection(120mg) was administered subcutaneously every 4 weeks for a maximum of 13 cumulative doses throughout the trial,according to the investigator's assessment.
Intervention: Xgeva
Outcomes
Primary Outcomes
uNTx/uCr
Time Frame: from baseline to week 13
Compare MW032 and Xgeva® for percentage change in bone conversion index (BTM) - urinary type I collagen cross-linked peptide (uNTx) adjusted for urinary creatinine (uCr) in Chinese subjects with solid tumor bone metastasis (uNTx/uCr from baseline to week 13)
Secondary Outcomes
- S-BALP(from baseline to weeks 5,13,25,37 and 53)
- uNTx/uCr(from baseline to weeks 5,25,37 and 53)
- SRE(from baseline to week 53)